Glenmark Pharmaceuticals Ltd on February 21 announced that its candidate for Rheumatoid Arthritis, Inflammation and Multiple Sclerosis - GRC 4039, has entered Phase I trials.
This is with approval from the Medicines and Healthcare Products Regulatory Agency [MHRA] in the U.K. The company intends to develop GRC 4039 for Rheumatoid Arthritis.
Glenmark expects to complete Phase I trials for GRC 4039 by October 2008 and initiate Phase II by January 2009.
Source: The Hindu Business Line © 2008, The Hindu Business Line (21/02/08)